Andrew Ip

1.5k total citations
66 papers, 415 citations indexed

About

Andrew Ip is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew Ip has authored 66 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 16 papers in Cancer Research and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew Ip's work include CAR-T cell therapy research (19 papers), Cancer Genomics and Diagnostics (14 papers) and Lymphoma Diagnosis and Treatment (12 papers). Andrew Ip is often cited by papers focused on CAR-T cell therapy research (19 papers), Cancer Genomics and Diagnostics (14 papers) and Lymphoma Diagnosis and Treatment (12 papers). Andrew Ip collaborates with scholars based in United States, Italy and India. Andrew Ip's co-authors include Jonathon B. Cohen, Irl Brian Greenwell, Noelle L. Williams, Adam P. Dicker, Shivank Garg, André Goy, Bassel F. El‐Rayes, David A. Kooby, Olatunji B. Alese and Jerome C. Landry and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Andrew Ip

50 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Ip United States 8 196 83 75 63 60 66 415
Sara Ekberg Sweden 15 197 1.0× 66 0.8× 221 2.9× 72 1.1× 49 0.8× 50 514
Cindy Lim Singapore 15 167 0.9× 109 1.3× 80 1.1× 25 0.4× 84 1.4× 36 560
C.A. Uyl-de Groot Netherlands 12 258 1.3× 54 0.7× 116 1.5× 71 1.1× 27 0.5× 28 553
Sze Chai Chan Hong Kong 12 131 0.7× 106 1.3× 23 0.3× 35 0.6× 39 0.7× 31 502
Thuan V. Tran Vietnam 11 168 0.9× 81 1.0× 61 0.8× 94 1.5× 43 0.7× 24 474
Ramy Saleh Canada 13 187 1.0× 59 0.7× 27 0.4× 28 0.4× 94 1.6× 57 397
Shuyi Wei China 11 108 0.6× 53 0.6× 24 0.3× 26 0.4× 61 1.0× 31 501
Chee Kian Tham Singapore 16 252 1.3× 138 1.7× 79 1.1× 70 1.1× 97 1.6× 40 653
Ruta Rao United States 13 307 1.6× 59 0.7× 49 0.7× 27 0.4× 117 1.9× 46 567
Neyran Kertmen Türkiye 11 333 1.7× 90 1.1× 47 0.6× 21 0.3× 150 2.5× 56 491

Countries citing papers authored by Andrew Ip

Since Specialization
Citations

This map shows the geographic impact of Andrew Ip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Ip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Ip more than expected).

Fields of papers citing papers by Andrew Ip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Ip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Ip. The network helps show where Andrew Ip may publish in the future.

Co-authorship network of co-authors of Andrew Ip

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Ip. A scholar is included among the top collaborators of Andrew Ip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Ip. Andrew Ip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kabat, Maciej, Andrew Ip, Hyung C. Suh, et al.. (2025). Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia. Transplantation and Cellular Therapy. 31(12). 1010–1019.
2.
Ahn, Jaeil, Brittany Sinclaire, Christina Cho, et al.. (2025). Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study. SHILAP Revista de lepidopterología. 6(1). 3–3. 1 indexed citations
3.
Ip, Andrew, Maciej Kabat, James J. De Voss, et al.. (2025). Updates on the Biological Heterogeneity of Mantle Cell Lymphoma. Cancers. 17(4). 696–696.
4.
Albitar, Maher, Andrew Ip, Sally Agersborg, et al.. (2024). Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer.. Journal of Clinical Oncology. 42(16_suppl). 3048–3048. 1 indexed citations
5.
Ip, Andrew, et al.. (2024). Clinical and sociodemographic factors associated with digital health literacy in patients with non-Hodgkin lymphoma or colorectal carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 1562–1562. 1 indexed citations
6.
7.
Ip, Andrew, et al.. (2024). Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis. Advances in Therapy. 41(3). 1226–1244. 5 indexed citations
8.
9.
Biran, Noa, David H. Vesole, Andrew J. Belli, et al.. (2024). Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT).. Journal of Clinical Oncology. 42(16_suppl). 7562–7562.
10.
Schwartz, Marc D., Heather M. Derry, John K. Marshall, et al.. (2024). Cancer survivor preferences on the timing and content of interventions to mitigate financial toxicity associated with cancer treatment. Supportive Care in Cancer. 32(12). 778–778.
11.
Feghali, Karine A. Al, Lydia Pascual, Michael Marafelias, et al.. (2023). Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of Failure after CAR T-Cell Therapy Eligible for Bridging Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 117(2). e463–e464.
12.
Devlin, Sean M., Beatriz Wills, Amethyst Saldia, et al.. (2023). Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy. Blood. 142(Supplement 1). 3510–3510. 1 indexed citations
13.
Ip, Andrew, Martin Gutierrez, Jing Zhang, et al.. (2023). Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma. Leukemia & lymphoma. 64(14). 2225–2235. 1 indexed citations
14.
15.
Ip, Andrew, et al.. (2023). Outcomes Analysis of Lenalidomide-Induced Rashes in Myeloma Patients. Blood. 142(Supplement 1). 6689–6689. 1 indexed citations
16.
Jegede, Opeyemi A., Brittany Sinclaire, Samir Gupta, et al.. (2023). 1418 Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan. SHILAP Revista de lepidopterología. A1576–A1577. 1 indexed citations
17.
Rosenthal, Allison, Javier Muñoz, Tongsheng Wang, et al.. (2023). P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS. HemaSphere. 7(S3). e9299527–e9299527.
18.
Albitar, Maher, Hong Zhang, Andrew Ip, et al.. (2023). Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors. Heliyon. 9(5). e16261–e16261. 14 indexed citations
19.
Ip, Andrew, et al.. (2022). Clotting events among hospitalized patients infected with COVID-19 in a large multisite cohort in the United States. PLoS ONE. 17(1). e0262352–e0262352. 5 indexed citations
20.
Ip, Andrew, Anthony R. Mato, Nicholas P. Howard, et al.. (2020). COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study. Blood. 136(Supplement 1). 6–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Ekberg Breakdown of academic impact, for papers by Cindy Lim Breakdown of academic impact, for papers by C.A. Uyl-de Groot Breakdown of academic impact, for papers by Sze Chai Chan Breakdown of academic impact, for papers by Thuan V. Tran Breakdown of academic impact, for papers by Ramy Saleh Breakdown of academic impact, for papers by Shuyi Wei Breakdown of academic impact, for papers by Chee Kian Tham Breakdown of academic impact, for papers by Ruta Rao Breakdown of academic impact, for papers by Neyran Kertmen
Rankless by CCL
2026